Table 1.
Main patient and tumors characteristics in the overall population
| Main baseline patient characteristics | n (%) |
|---|---|
| Age, median (range) | 55 (27–82) |
| ECOG PS | |
| 0 | 210 (67) |
| 1–2 | 104 (33) |
| Histology | |
| Ductal | 275 (87.6) |
| Lobular | 29 (9.2) |
| Other | 10 (3.2) |
| Hormone receptor and HER‐2 status at initial diagnosis | |
| ER and/or PgR positive | 254 (80.9) |
| Triple negative | 50 (15.9) |
| HER2 positive | 3 (1.0) |
| Unknown | 7 (2.2) |
| KI67 | |
| >14% | 211 (67.2) |
| ≤14% | 103 (32.8) |
| Neoadjuvant /Adjuvant treatment | |
| Neoadjuvant chemotherapy | 78 (24.8) |
| Adjuvant chemotherapy | 181 (57.6) |
| Adjuvant taxanes | 104 (33.1) |
| Adjuvant endocrine therapy | 211 (67.2) |
| Adjuvant radiotherapy | 161 (51.3) |
| Metastatic at diagnosis | |
| Yes | 55 (17.5) |
| No | 259 (82.5) |
ECOG PS, eastern cooperative oncology group performance status; ER, estrogen receptor; PgR, progesterone receptor; n, number.